This is Theresa Agnew, CEO of BioGaia, and I am here with Alexander Kotsinas, and we are here to present our Q2 2026 results. Some of the highlights of the quarter are that growth, excluding currency effects, was 12% versus a year ago. Our EBIT margin is 30%, with an adjusted EBIT margin of 33% for the quarter. Overall, our net sales reached 441 million SEK. As I said, with growth excluding currency effects of 12%, specifically in the regions in EMEA, our sales increased by 21%, excluding currency effects.
In the Americas, sales increased by 16% excluding currency effects, while Asia-Pacific decreased by 6% excluding currency effects due to order variability. Our operating profit in the quarter was 132 MSEK, which is an increase of 22%, and our EBIT margin was 30% versus the 27% last year for Q2; our adjusted EBIT margin was 33% for the quarter. Overall, our net sales year-to-date reached 813 MSEK, representing growth of 13% excluding currency effects. Our BioGaia company strategy remains the same. Our first strategic pillar is to grow the core, the core being our health areas of business, of which gut health, including colic, oral health, and immune health, are our biggest priorities. Our second strategic pillar is what we call expansion through direct markets, where we look at particular markets to transition from a distributor partnership to a subsidiary or direct market. We currently have 12 direct markets, and our third strategic pillar is breakthrough innovation. This is a market creation opportunity for probiotics, where people do not routinely use probiotics today. The foundations of our company are people and culture, investing for profitable growth, using digital as an enabler, both in how we go to market through our omnichannel approach, as well as digitizing our business internally, driven by science, which has been a foundation for over 30 years, and sustainable solutions, highlighting the importance of sustainability to our business.
So, how are we delivering on our strategy in terms of growing the core? In the quarter, we drove growth for both the Pediatric and Adult Health segments. We are investing in our marketing and selling activities to drive strong growth in our direct markets. We are continuing to roll out our new products. We had originally launched BioGaia Gastrus Pure Action in October of 2024. We continue to roll that out this year. We also launched last year BioGaia Prodentis Fresh Breath. We are continuing to roll that out to more markets this year. And we just recently in May launched our next generation patented probiotic drops called BioGaia Protectis Plus. BioGaia Protectis Plus. BioGaia Protectis Plus will be available in addition to our original Protectis drops. And in terms of expansion through direct markets, we continued our rollout in Germany and Austria in Q2, which originally launched in January of this year. One of our largest markets, the US, had record sales in Q2, and we have seen strong performance in France in Q2 in terms of our breakthrough innovation. Skin health is one of our exciting new areas, and we expanded our portfolio in the quarter with two additional new products and updated our design across the full range. So some of the launches that we had in the quarter, as I mentioned, we launched BioGaia Protectis Plus; we launched that in the UK, Ireland, as well as in Sweden. We launched our Pharax drops in a number of markets. As I mentioned, we launched our two new skincare products. So, a face and body lotion and a balm-to-milk body wash, both microbiome-friendly and containing organic ingredients. And those launches happened in the US and China.
Some of the key events for the quarter. On April 28th, we published some new scientific findings on one of our patented technologies. It is called LongevityGuard. It is a desiccant technology that goes into our drops products and our probiotic ointment that improves the stability and shelf life of our probiotics so that they remain viable throughout the shelf life. On May 7th, we announced the launch of BioGaia Protectis Plus, which is, as I mentioned, a proprietary patented combination of our strain DSM 17938, as well as BG-R46. Also on May 7th, at our Annual General Meeting, we elected a new board member to our Board of Directors. Amy Byrick. And then on June 18th, we announced the new product launches that I mentioned, the lotion and wash for the BioGaia skincare portfolio.
Our growth, as I said, for Q2, was 12% organic growth. As you look at it from a pediatric and adult segment standpoint, the pediatric segment grew 9% organically, and the adult segment grew 23% organically. And a little bit more on the segments if you look at the quarter. As I said, excluding currency effects, Pediatrics grew 9% and Adult Health grew 23%. But if you look at the total for the year-to-date, the Pediatric segment grew 11% organic growth and Adult Health grew 21%. In terms of pediatrics for the quarter, sales mainly increased in France, the US, and Brazil. In terms of adult health, sales increased in our BioGaia Protectis tablets, and sales also increased in Asia Pacific, mainly in Indonesia and Japan. So overall, our pediatric segment for the quarter accounts for 75% of our sales. And year to date is 74% of our sales.
Now by region, as I said previously, Europe, Middle East, and Africa increased by 21%, excluding currency effects, mainly in France and Poland. These were strong markets for us.
In addition, other strong markets in EMEA were Germany as well as the UK. In Asia Pacific, our sales decreased by 6% excluding currency effects. Sales were lower in our pediatric segment, while the adult health segment did increase. As I mentioned previously, the sales were lower, mainly in China and South Korea. This was due to quarterly variations for individual orders. So, order variability. And in the Americas, which includes Latin America as well as North America, our sales increased by 16%, excluding currency effects. This is due to higher sales in both the Pediatric segment and the Adult Health segment, and sales increased mainly in the US, Canada, and Argentina. I will now turn it over to Alexander Kotsinas to go through the financials in more detail.